From GlobeNewswire:



CVRx, Inc. announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 3:45pm Pacific Time via a webcast available on the Company’s website.

CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™, the first medical technology approved by the FDA that uses neuromodulation to improve symptoms of patients with heart failure, delivers electrical pulses to carotid arteries to restore balance to the autonomic nervous system and reduce symptoms of heart failure. The product is FDA and CE approved.

Investors and media contacts for CVRx are Mark Klausner/Mike Vallie and Laura O’Neill, respectively.

The main point of this article is to inform readers that CVRx will be presenting at a healthcare conference and to provide background information about the company and its product.



Read more: CVRx to Present at the 42nd Annual J.P. Morgan Healthcare